MDS Pharma extends central lab operations in China

With almost 25,000 square feet, the new facility offers a five-times increase in testing capacity, four times the space to produce clinical trial kits, and a wider range of specialized clinical trial testing services. The new central lab facility specializes in molecular biology testing for infectious diseases, DNA banking and pharmacogenomics, the study of genes to develop therapies tailored to a person’s genetic makeup.

It also offers enhanced molecular biology techniques, a microbiology lab and flow cytometry capabilities, a technology used increasingly in oncology and immune disorders.

David Spaight, MDS Pharma Services president, said: “We are excited about how this significant expansion will better serve the growing needs of our clients. With many pharmaceutical and biotech companies now making China part of their global clinical trial programs, we recognized the need to expand our central lab operations and offer more diverse testing options.”